Anti-MBL autoantibodies in patients with rheumatoid arthritis: prevalence and clinical significance

Gupta, Bhawna; Raghav, Sunil K.; Agrawal, Charu; Chaturvedi, Ved; Das, Rakha H.; Das, Hasi R.

doi:10.1016/j.jaut.2006.07.002

Cited by 35 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of this study showed an obvious measurable and a higher significant presence of anti-MBL autoantibodies in the sera of enrolled RA cases (meanSD=394±243 ng/ml) as compared with healthy controls (meanSD=217±173 ng/ml)(p=0.001). This result was similar to that reported by Gupta et al 26 in India which showed a detectable significant presence of anti-MBL autoantibodies in the sera of RA patients as compared to the controls. This study demonstrated that the anti-MBL were more often in RA patient sera and suggested that it have a diagnostic value for RA.…”

Section: Discussionsupporting

confidence: 92%

“…Our results were in agreeing with study by Di Muzio et al 27 , and disagree with study by Gupta et al which reported that the levels of anti-MBL antibodies were still positive and high in negative cases of RF and CRP 26 . As regard ACPA, there was no association between positive ACPA and the levels of anti-MBL autoantibodies, in which the meanSD of anti-MBL levels for ACPA positive cases was 376.8257 ng/ml, and for negative ACPA were 415.4208 ng/ml.…”

Section: Issn: 2456-8058contrasting

confidence: 53%

See 1 more Smart Citation

Seroprevalence of Anti-Mannose Binding Lectin Autoantibodies in Patients With Rheumatoid Arthritis in Sana'a City- Yemen

El-Aghbary

Al-Jaaidi

Al-Moyed

et al. 2018

UJPR

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) characterized by synovial inflammation and destruction of cartilage and bone. Until now there is no single test that diagnoses RA, however, several blood tests may suggest the presence of this disease. RA is associated with the presence of a number of autoantibodies as such as rheumatoid factor (RF), anti-cyclic citrullinated peptide (ACPA) and antimannose binding lectin (anti-MBL). This study aimed firstly to investigate the presence of anti-MBL autoantibodies in the sera of RA patients and healthy controls and secondly to determine the diagnostic value of this marker in comparison with the classical RF, C-reactive protein (CRP) and ACPA among RA cases. This case-control study was conducted at four health establishments; two public (Al-Thawra Modern General Hospital and National Center of Central Public Health Laboratories) and two private (University of Science and Technology Hospital and Aulqi Specialized Medical Laboratories) in Sana'a city. Ninety-four individuals were enrolled in this study. Forty-seven persons were clinically diagnosed to have RA by a rheumatologist and 47 healthy subjects without RA were used as controls. Sera were separated and tested for presence of serum anti-MBL autoantibodies, ACPA, RF and CRP by a commercially available enzyme linked immunosorbent assay (ELISA) and latex agglutination technique. Study results showed that the meanSD for the levels of serum anti-MBL autoantibodies among RA cases were 394243 ng/ml which were significantly higher than that recorded among healthy controls (217173 ng/ml). The levels of serum anti-MBL autoantibodies were associated with positive RF and CRP tests (p=.02 and .007 respectively), but not with positive ACPA test (p=.42). The result of this study showed higher levels of serum anti-MBL autoantibodies among RA cases comparing with the healthy controls and reveal an association with positive results for RF and CRP, but not with ACPA. Therefore, the anti-MBL antibody levels may associated with systemic autoimmune diseases and might not exclusive to RA.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Issn: 2456-8058contrasting

confidence: 53%

Seroprevalence of Anti-Mannose Binding Lectin Autoantibodies in Patients With Rheumatoid Arthritis in Sana'a City- Yemen

El-Aghbary

Al-Jaaidi

Al-Moyed

et al. 2018

UJPR

View full text Add to dashboard Cite

show abstract

“…In comparison with both IgM and IgG isotypes of rheumatoid factor, anti-MBL autoantibodies were found more often in the RA patient sera and could therefore have a diagnostic value for RA as suggested by the authors. Anti-MBL autoantibodies were also found in synovial fluid from several RA patients [139].…”

Section: :2 Autoantibodies Against Mblmentioning

confidence: 92%

“…In addition, MBL binds both dimeric and polymeric IgA and activates complement [134]; it binds agalactosyl IgG and IgM, including IgM rheumatoid factor complexes from RA patients [135]. Occurrence of autoantibodies against MBL (anti-MBL) has been reported by several groups [136][137][138][139]. Seelen and coworkers demonstrated significant higher levels of anti-MBL in SLE patients as compared to healthy subjects, but with no correlation with disease activity or specific organ involvement [136].…”

Section: :2 Autoantibodies Against Mblmentioning

confidence: 99%

“…No significant correlation between anti-MBL antibody levels and serum MBL or any specific lupus feature was found [137]. Mok et al [138] Recently, the first study on anti-MBL autoantibodies in RA was presented [139]. Gupta et al investigated sera from 107 patients with established RA of which 65 were anti-MBL antibody positive, and 121 healthy controls of which only 2 were anti-MBL antibody positive.…”

Section: :2 Autoantibodies Against Mblmentioning

confidence: 99%

See 1 more Smart Citation

Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteins

Sjöwall

Wetterö

2007

Clinica Chimica Acta

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a systemic rheumatic disease characterized clinically by multiorgan involvement and serologically by the occurrence of antinuclear antibodies. SLE patients may present with multiple autoantibodies to cytoplasmic and cell surface antigens as well as to circulating plasma proteins. Another feature of SLE is that serum levels of C-reactive protein (CRP) often remain low despite high disease activity and despite high levels of other acute phase proteins and interleukin-6, i.e. the main CRP inducing cytokine. Apart from its important role as a laboratory marker of inflammation, CRP attracts increasing interest due to its many intriguing biological functions, one of which is a role as an opsonin contributing to the elimination of apoptotic cell debris, e.g. nucleosomes, thereby preventing immunization against autoantigens. Recently, autoantibodies against CRP and other acute phase proteins have been reported in certain rheumatic conditions, including SLE. Although the presence of anti-CRP autoantibodies does not explain the failed CRP response in SLE, antibodies directed against acute phase proteins have several implications of pathogenetic interest. This paper thus highlights the biological and clinical aspects of native and monomeric CRP and anti-CRP, as well as autoantibodies against mannose-binding lectin, serum amyloid A and serum amyloid P component. © 2006 Elsevier B.V. All rights reserved

show abstract

Comparison of Three Anti-CCP Antibody Tests and Rheumatoid Factor in RA and Control Patients

Correia¹,

Carvalho²,

Fortuna

et al. 2007

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Sera from 86 RA patients and 90 control patients with other diseases, such as infections, connective tissue diseases, or other rheumatic diseases, were analysed using the four different methods. Specificity (84.4%) and PPV (80.3%) were lowest for RF IgM and highest for EliA CCP (specificity 97.8%, PPV 96.7%), the other values being close to those of EliA CCP. Sensitivity was highest for Quanta Lite CCP (73.3%). Efficiency was highest for Quanta Lite CCP (84.1%) at the lower cut off followed by EliA CCP at both cut offs (83.0%). The discrimination between RA sera (mean value 407.67 U/ml) and control sera (4.54 U/ml) and the relative risk (23.34) were best for EliA CCP. The results of this study reveal that there was no advantage of the anti-CCP antibodies assay applying a new antigen mixture (Quanta Lite CCP 3 ELISA) compared to two second generation anti-CCP antibodies assays (Quanta Lite CCP ELISA and EliA CCP).

show abstract

Anti-MBL autoantibodies in patients with rheumatoid arthritis: prevalence and clinical significance

Cited by 35 publications

References 27 publications

Seroprevalence of Anti-Mannose Binding Lectin Autoantibodies in Patients With Rheumatoid Arthritis in Sana'a City- Yemen

Seroprevalence of Anti-Mannose Binding Lectin Autoantibodies in Patients With Rheumatoid Arthritis in Sana'a City- Yemen

Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteins

Comparison of Three Anti-CCP Antibody Tests and Rheumatoid Factor in RA and Control Patients

Contact Info

Product

Resources

About